Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis

Gareth Pryce, Janet K O'Neill, J Ludovic Croxford, Sandra Amor, Deborah J Hankey, Emma East, Gavin Giovannoni, David Baker

Research output: Contribution to journalArticleAcademicpeer-review

74 Citations (Scopus)


To date there has been poor translation of immunotherapies from rodent models to treatment of progressive multiple sclerosis (MS). In the robust, relapsing Biozzi ABH mouse model of MS, using a combination of a transient deletion of T cells followed by intravenous (i.v.) myelin antigen administration, established relapsing disease in EAE can be effectively silenced. However, when treatment was initiated in late stage chronic-relapsing disease, despite inhibition of further relapses, mice demonstrated evidence of disease progression shown by a deterioration in mobility and development of spasticity and indicates that targeting relapsing, immunological components of MS alone is unlikely to be sufficient to control progression in the late stages of MS.

Original languageEnglish
Pages (from-to)41-52
Number of pages12
JournalJournal of Neuroimmunology
Issue number1-2
Publication statusPublished - Aug 2005


  • Adoptive Transfer
  • Animals
  • Antibodies, Monoclonal
  • CD4 Antigens
  • Chronic Disease
  • Disease Models, Animal
  • Disease Progression
  • Drug Therapy, Combination
  • Encephalomyelitis, Autoimmune, Experimental
  • Immune Tolerance
  • Injections, Intravenous
  • Journal Article
  • Lymphocyte Depletion
  • Mice
  • Mice, Biozzi
  • Mice, SCID
  • Multiple Sclerosis, Chronic Progressive
  • Multiple Sclerosis, Relapsing-Remitting
  • Myelin Proteolipid Protein
  • Research Support, Non-U.S. Gov't
  • Secondary Prevention
  • Spinal Cord
  • Spleen

Cite this